GSK•benzinga•
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
Summary
Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 6, 2025 by benzinga